I appreciate the commentary from Garner on our article.1 We emphasized in our original article the narrow therapeutic window for HBO treatment in burned mice. The fact that we found an increased mortality rate in HBO-treated mice, even at the safest dose, reflects the potential danger of HBO therapy during acute burn shock. At this time, we do not know the reason(s) for the increased mortality rate, although I would speculate that it may relate to an increased production of high-energy oxygen compounds by leukocytes sequestered in tissues. We hope to be able to prove this in the future. As we stated in our final paragraph, "clinical studies of HBO treatment for acute burn management should proceed cautiously."